<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-2891</journal-id>
<journal-title><![CDATA[Revista científica ciencias de la salud]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. cient. cienc. salud]]></abbrev-journal-title>
<issn>2664-2891</issn>
<publisher>
<publisher-name><![CDATA[Universidad del Pacífico]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-28912020000200019</article-id>
<article-id pub-id-type="doi">10.53732/rccsalud/02.02.2020.19</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectividad de la furosemida nebulizada en el tratamiento de la crisis asmática severa en niños]]></article-title>
<article-title xml:lang="en"><![CDATA[Effectiveness of nebulized furosemide in the treatment of severe asthma attack in children]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Leónidas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cardozo]]></surname>
<given-names><![CDATA[Eva]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morilla]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pavlicich]]></surname>
<given-names><![CDATA[Viviana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital General Pediátrico de Acosta Ñu Departamento de Urgencias ]]></institution>
<addr-line><![CDATA[San Lorenzo ]]></addr-line>
<country>Paraguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad del Pacífico Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Asunción ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>2</volume>
<numero>2</numero>
<fpage>19</fpage>
<lpage>24</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2664-28912020000200019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2664-28912020000200019&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2664-28912020000200019&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Introducción: La hiperosmolaridad de las secreciones por las altas concentraciones de iones se ha correlacionado con la hiperreactividad bronquial, esto llevó a considerar el uso de la furosemida inhalada como tratamiento adicional en el asma bronquial. Objetivo: Evaluar si la administración de la furosemida nebulizada asociado al tratamiento convencional del asma severo en pacientes mayores de 5 años disminuye el tiempo de crisis y la permanencia en el Departamento de Emergencia (DE). Metodología: Estudio randomizado controlado de pacientes con exacerbación asmática severa en un DE. Se excluyeron pacientes con comorbilidad. Los sujetos fueron aleatorizados recibiendo en la nebulización, el grupo experimental: furosemida, salbutamol e ipratropio y el grupo control: salbutamol e ipratropio. Y el resto del tratamiento farmacológico fue igual en ambos grupos. El primer punto de corte fue el descenso del score en más de 2 puntos a las 2 h del tratamiento; los puntos secundarios fueron descenso del score a las 6 h, tiempo de permanencia en el departamento de emergencia e ingreso a UCIP. Resultados: Los grupos experimental (n: 46) y control (n: 36) presentaron características basales similares. La proporción de sujetos con disminución de más de dos puntos en el score a las 2 h de tratamiento y fue de 76% en el experimental versus el control que fue de 82 % (p = 0,323). La estadía media fue 19,2±10,35 h en el experimental versus 19,7±14,5 h en el control (p = 0,670). No se encontraron diferencias significativas en el score y puntaje del esfuerzo respiratorio en las mediciones cada 2 horas. Conclusión: La furosemida nebulizada no mejoró de manera significativa los parámetros clínicos ni la estancia en el DEP.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT The hyperosmolarity of the secretions due to high ion concentrations has been correlated with bronchial hyperresponsiveness. This led to the consideration of the first uses of inhaled furosemide as an additional treatment for bronchial asthma. Objective: To assess whether the administration of nebulized furosemide as an adjunct medicine associated with conventional treatment of severe asthma in patients older than 5 years weighing &#8805;20 kg decreases the time of crisis and the stay in the Emergency Department (ED). Methodology: Randomized controlled study of patients with severe asthma exacerbation in a PED. Patients with comorbidity were excluded. The subjects were randomized into: Group 1 (Experimental) (n = 46): Furosemide associated with salbutamol and nebulized ipatropium and Group 2 (Control) (n = 36): Nebulization with Salbutamol and Ipratropium. Both groups received the usual pharmacological treatment. The first cut-off point was a decrease in the score by more than 2 points at 2 h after treatment; secondary points were decrease in score at 6 h, time spent in the emergency department and admission to the PICU. Results: The baseline characteristics were similar in both groups. The proportion of subjects with a decrease of more than two points in the score at 2 h of treatment in Group 1 was 76% compared to Group 2, which was 82% (p = 0.323). The mean stay was 19.2 ± 10.35 h in Group 1 vs 19.7 ± 14.5 h in Group (p = 0.670). No significant differences were found in the score and score of respiratory effort in measurements every 2 hours. Conclusion: Nebulized furosemide as an adjunct drug in the treatment of severe asthma did not significantly improve the clinical parameters or the stay in the PED.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[furosemida]]></kwd>
<kwd lng="es"><![CDATA[salbutamol]]></kwd>
<kwd lng="es"><![CDATA[ipratropio]]></kwd>
<kwd lng="en"><![CDATA[furosemide]]></kwd>
<kwd lng="en"><![CDATA[salbutamol]]></kwd>
<kwd lng="en"><![CDATA[ipratropium]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Etxaniz]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Raso]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protocolos diagnóstico-terapéuticos de Urgencias Pediátricas]]></article-title>
<source><![CDATA[SEUP-AE]]></source>
<year>2013</year>
<volume>6</volume>
<numero>^s10</numero>
<issue>^s10</issue>
<supplement>10</supplement>
<page-range>52-62</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martínez Peréz]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Bermudez]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Asma bronquial y Furosemida]]></article-title>
<source><![CDATA[Revista Electrónica Zoilo]]></source>
<year>2014</year>
<volume>39</volume>
<numero>8</numero>
<issue>8</issue>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Powell]]></surname>
<given-names><![CDATA[CV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Acute Severe asthma]]></article-title>
<source><![CDATA[J Paediatr Child Health]]></source>
<year>2016</year>
<volume>53</volume>
<page-range>187-91</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masoumi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Forouzan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Haddadzadeh Shoushtari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Porozan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Feli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fallah Bagher Sheidaee]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Efficacy of Nebulized Furosemide and Salbutamol Compared with Salbutamol Alone in Reactive Airway Disease: A Double Blind Randomized]]></article-title>
<source><![CDATA[Clinical Trial Emerg Med Int]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hechavarría Miyares]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Carreras Corzo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Vázquez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Azze Pavón]]></surname>
<given-names><![CDATA[MÁ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Uso de la furosemida inhalada en el asma bronquial]]></article-title>
<source><![CDATA[Rev Cubana Salud y trabajo]]></source>
<year></year>
<volume>1</volume>
<numero>2-3</numero>
<issue>2-3</issue>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Macdonald]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ollerton]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Krum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nebulized Furosemide for the Management of Dyspnea: Does the Evidence Support Its Use]]></article-title>
<source><![CDATA[J Pain Symptom Manage]]></source>
<year>2008</year>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>424-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inokuchi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yahagi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of inhaled furosemide for acute asthma exacerbation: a meta-analysis]]></article-title>
<source><![CDATA[Crit Care]]></source>
<year>2014</year>
<volume>18</volume>
<page-range>62</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
<name>
<surname><![CDATA[Trujillo]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Huerta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vasquez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Trujillo]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Furosemide plus albuterol compared with albuterol alone in children with acute asthma]]></article-title>
<source><![CDATA[Allergy Asthma Proc]]></source>
<year>2002</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>181-4</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nuho&#287;lu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ya&#351;ar Kiliç]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ceran]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness of nebulized furosemide added to nebulized salbutamol in children with acute asthma]]></article-title>
<source><![CDATA[Allergol et Immunopathol]]></source>
<year>2006</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>54-8</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alshehri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Almegamesi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Alfrayh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of nebulized furosemide in children with moderate attack of asthma]]></article-title>
<source><![CDATA[West Afr J Med]]></source>
<year>2005</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>246-51</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
